Teriparatide / pTH (1-34) (human) Acetate manufacturer
Product Code: 4158068 Product Code GMP: H-4835-GMP
Key information
Regulatory documentation
DMF: available
Chemical identifiers
CAS Number(s):
- 52232-67-4 (net)
- 99294-94-7 (acetate)
Synonyms: Parathyroid hormone (1-34) (human)
Sequence
H-Ser-Val-Ser-Glu-Ile-Gln-Leu-Met-His-Asn-Leu-Gly-Lys-His-Leu-Asn-Ser-Met-Glu-Arg-Val-Glu-Trp-Leu-Arg-Lys-Lys-Leu-Gln-Asp-Val-His-Asn-Phe-OH acetate salt
Fields of application
- Osteoporosis
- Diagnosis of hypoparathyroidism
Active substance
pTH (1-34) (human) corresponds to N-terminal part of human parathyroid hormone, a peptide consisting of 84 amino acids. pTH (1-34) (human) shows the same activity and pharmacological profile as the native peptide hormone.
Intermittent administration of pTH (1-34) (human) acetate in low dosage stimulates bone formation and increases bone mineral density.
Bachem’s pTH (1-34) (human) is obtained by chemical synthesis.
Molecular Information
Molecular formula:
C181H291N55O51S2
Relative molecular mass:
4117.77 g/mol
Long-term storage:
-20 ± 5°C
Why choose Bachem as your Teriparatide API supplier
Market-leading expertise
Bachem brings over five decades of peptide‑chemistry leadership, making them one of the most trusted global partners for complex Peptide APIs.
High-yield GMP manufacturing
Our advanced production capabilities deliver consistently high yields and GMP‑certified quality, ensuring reliable performance across every batch.
Robust regulatory support
Bachem provides comprehensive regulatory documentation – including DMFs and European Pharmacopoeia Certificates – streamlining global submissions and compliance.
Secure, stable supply chain
With ample inventory, strong impurity management, and efficient logistics, Bachem ensures dependable, uninterrupted supply for commercial and clinical needs.
Cutting-edge SPPS technology
Our expertise of solid‑phase peptide synthesis enables precise sequence control and high‑purity production of pTH (1‑34).
Streamlined customer experience
Fast shipping, flexible order sizes, and smooth documentation handling make procurement simple and efficient for customers worldwide.
Driving generic drugs together
Rely on our years of experience in manufacturing Peptide APIs for your next commercial drug venture.
Additional information on Teriparatide
Teriparatide is derived from the human parathyroid hormone
Teriparatide, an active pharmaceutical ingredient (API), is a fragment of the human parathyroid hormone (PTH), which plays a crucial role in regulating calcium levels, bone remodeling, and kidney functions. The parathyroid hormone (PTH) is a polypeptide containing 84 amino acids, produced by the parathyroid glands located near the thyroid gland in the neck. When calcium levels in the blood decrease, PTH is secreted, initiating the breakdown of bone tissue to release calcium. This hormone not only facilitates the reabsorption of calcium in the kidneys but also activates the conversion of vitamin D into calcitriol, enhancing calcium absorption from the intestines. Teriparatide replicates the 34 N-terminal amino acids of PTH, embodying its potent bone-forming capabilities.
Teriparatide stimulates bone formation
Both the full-length PTH and its fragment, Teriparatide (PTH 1-34), play a dual role in bone metabolism–both resorbing and forming bone. The balance between these actions is key in managing serum calcium levels. Continuous exposure to high levels of PTH can result in excessive calcium release from bones, leading to osteoporosis. However, Teriparatide, when used therapeutically, is administered intermittently, mimicking the natural pulsatile release of PTH. This mode of administration works to encourage osteoblast (bone-building cells) activity, helping bone formation and offering a therapeutic way of treating osteoporosis. By doing it this way Teriparatide not only mitigates the risk of osteoporosis but actively reverses its course by enhancing bone formation and increasing bone mass strength. This therapeutic approach provides a significant benefit in the treatment and management of osteoporosis, offering a targeted strategy to improve bone health and patient outcomes.
Teriparatide can be manufactured by solid phase peptide synthesis
Initially approved in the United States in 1987 as a diagnostic agent for parathyroid conditions and later in 2002 with the FDA approval for the treatment of osteoporosis in men and postmenopausal women who are at high risk of having a fracture. Teriparatide was originally produced recombinantly, but its synthetic version, called pTH (1-34) has been synthesized using the sophisticated technique of solid-phases peptide synthesis (SPPS).
SPPS is renowned for its ability to assemble peptides with high precision, which is critical for producing peptides like Teriparatide with the required specificity and activity. This method involves the sequential addition of protected amino acid residues to a growing peptide chain, which allows for the creation of exact peptide sequences necessary for biological activity.